GHK-Cu's shorter evidence trail reflects investment gaps, not inferior biology
10.1016/j.freeradbiomed.2017.08.008 37 GomarS.BouR.PuertasF
Sometimes its not all in your headits oxidative stress
Pharm Innov J 7:178181 Anraku M, Gebicki JM, Iohara D, Tomida H, Uekama K, Maruyama T, Hirayama F, Otagiri M (2018) Antioxidant activities of chitosans and its derivatives in in vitro and in vivo studies
STEP 1 trial (Wilding et al., NEJM 2021) the one that sparked much of the global excitement around GLP-1s: The mean change in body weight from baseline to week 68 was 14.9 % in the semaglutide group as compared with 2.4 % with placebo Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo. For the first time, a medication could achieve double-digit, sustained weight loss alongside meaningful improvements in health and daily function